Athena Athena

X
[{"orgOrder":0,"company":"Exothera","sponsor":"CyanVac","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CyanVac Selects Exothera for the Development and GMP Manufacturing of Its Covid-19 Intranasal Vaccine Candidate for Phase III Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"BELGIUM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Exothera","sponsor":"Rokote Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rokote Laboratories Selects Exothera For GMP Manufacturing of Its Second-\u200bgeneration Coronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"BELGIUM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Exothera","sponsor":"Valo Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Valo Therapeutics Selects Exothera to Develop Large-Scale Oncolytic Adenovirus Manufacturing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Exothera","sponsor":"Remedium","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Remedium and Exothera Partner On Scale-up And Demonstration Runs For AAV2-FGF18","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical"}]

Find Clinical Drug Pipeline Developments & Deals by Exothera

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Remedium and Exothera will demonstrate the industrialization potential of Remedium’s RMD 1101 (AAV2-FGF18). Remedium’s lead candidate is the only disease modifying gene therapy based on the clinically proven regenerative mechanism of FGF18 for the treatment of rheumatology.

            Lead Product(s): RMD 1101

            Therapeutic Area: Musculoskeletal Product Name: RMD 1101

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Remedium

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration March 22, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            VALO-D102 is a fundamental component of the company’s proprietary PeptiCRAd (peptide-coated Conditionally Replicating Adenovirus) immuno-oncology platform. PeptiCRAd combines two cancer immunotherapy approaches: an oncolytic Adenovirus and a peptide vaccine.

            Lead Product(s): VALO-D102

            Therapeutic Area: Oncology Product Name: VALO-D102

            Highest Development Status: Discovery Product Type: Large molecule

            Recipient: Valo Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement January 11, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The FINCoVac vaccine is designed to program the nasopharyngeal cells to produce immune response-inducing modified SARS-CoV-2-viral spike protein. FINCoVac 2.0 represents an easy-to-administer booster for those who are already fully vaccinated with other coronavirus vaccines.

            Lead Product(s): FINCoVac 2.0

            Therapeutic Area: Infections and Infectious Diseases Product Name: FINCoVac 2.0

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Rokote Laboratories

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership April 01, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Exothera will be responsible for the fast-track development of a manufacturing process for CyanVac’s COVID-19 vaccine candidate, CVXGA1, using the unique scale-X™ platform.

            Lead Product(s): CVXGA1

            Therapeutic Area: Infections and Infectious Diseases Product Name: CVXGA1

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: CyanVac

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration March 24, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY